SITAVIG

PeakSM

acyclovir

NDABUCCALTABLET

Approved

Apr 2013

Lifecycle

Peak

Competitive Pressure

8/100

Clinical Trials

Clinical Trials (5)

NCT05098938Phase 3Completed

A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally

Started Nov 2021

2,020 enrolled

Recurrent Herpes Labialis

NCT04988646N/ACompleted

Pharmacokinetic Properties of 200 and 400 mg Acyclovir Tablet in Indonesia Healthy Subject

Started Feb 2020

56 enrolled

Drug Use

NCT04664127N/ACompleted

Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel

Started Oct 2017

NCT03073967Phase 3Completed

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

Started May 2017

158 enrolled

HSV Infection

NCT01453075Phase 1Completed

Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)

Started Nov 2011

31 enrolled

Chronic Hepatitis C Infection